Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.66 |
| ▸ | KDR | P35968 | 8/20 | 0.66 |
| ▸ | KIT | P10721 | 3/20 | 0.65 |
| ▸ | AXL | P30530 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824916 | 0.93 | PDGFRA (0.76) | METPDGFRAKDRKITAXL | |
| SCHEMBL2747758 | 0.90 | MET (1.00) | METPDGFRAKDRKITAXL | |
| SCHEMBL4548867 | 0.88 | MET (0.96) | METPDGFRAKDRKITAXL | |
| SCHEMBL5824674 | 0.88 | MET (0.63) | METPDGFRAKDRKITAXL | |
| SCHEMBL5825089 | 0.87 | PDGFRA (0.77) | METPDGFRAKDRKITFLT3 | |
| SCHEMBL5825421 | 0.87 | PDGFRA (0.78) | METPDGFRAKDRKITAXL | |
| SCHEMBL5824938 | 0.87 | PDGFRA (0.78) | METPDGFRAKDRKITAXL | |
| SCHEMBL4548860 | 0.86 | MET (0.80) | METPDGFRAKDRKITAXL | |
| SCHEMBL2747795 | 0.86 | MET (0.75) | METPDGFRAKDRKITAXL | |
| SCHEMBL2747522 | 0.85 | MET (0.73) | METPDGFRAKDRKITAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | MET 3/4885PDGFRA 49/4885KDR 354/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | MET 3/4885PDGFRA 49/4885KDR 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.